CytoDyn Jumps on Approval to Treat Severe Covid-19 Cases

CytoDyn gained as much as 16% Wednesday, heading for its highest close since 2011, after the biotech company said it filed a second clinical trial protocol with the FDA to treat severely ill Covid-19 patients with leronlimab.

• Trial will be conducted under the same FDA-approved IND as Phase 2 clinical trial to treat Covid-19 patients with mild to moderate indications
• Leronlimab has been administered to 10 severely ill patients in the New York City area
  • New protocol is for 342 patients

To contact the reporter on this story:
Kristine Owram in New York at kowram@bloomberg.net

To contact the editors responsible ...